Clinical trials
Recurrent Solid Tumor clinical trials
Below are recruiting recurrent solid tumor clinical trials, each written for real people, not researchers. We’re tracking 462 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07303387RecruitingPhase 2
Valemetostat for solid tumors with SWI/SNF gene changes
This trial tests a new drug, valemetostat, for solid tumors that have specific genetic changes (like loss of SMARCB1, SMARCA4, or ARID1A). It is for people whose cancer has continued to grow despite other treatments. The study will see if valemetostat can help shrink or slow tumors.
Villejuif, Val de MarneAges 18 years+ - NCT07269899RecruitingPhase 1
A study of WTX212A with or without radiation for advanced cancer
This trial tests a new drug (WTX212A) alone or with radiation therapy for people with advanced solid tumors. It aims to see if the treatment is safe and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT06716619RecruitingPhase 1
Immune cell therapy for advanced solid tumors
This trial tests a new immune cell treatment made from your own lymph nodes for advanced solid tumors that haven't responded to standard therapies or have no good treatment options. It aims to see if this personalized cell therapy is safe and can help shrink tumors.
Guangzhou, GaungdongAges 18–75 - NCT05784688RecruitingPhase 1/Phase 2
TU2218 with Keytruda for advanced solid tumors
This trial studies TU2218 taken with Keytruda (pembrolizumab) in adults with advanced solid cancers that have limited treatment options. The goal is to see if the combination can shrink tumors and is safe enough to keep using.
San Antonio, TexasAges 18 years+ - NCT05916248RecruitingEarly Phase 1
mRNA vaccine plus pembrolizumab for advanced solid tumors
This trial tests whether a personalized mRNA vaccine, given with pembrolizumab, can help people with advanced solid tumors by training the immune system to recognize cancer. It is mainly for patients whose tumor tissue matches specific genetic and immune patterns, and who meet key safety and infection requirements.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06621563RecruitingPhase 1
Study of HS-20117 Combination Therapy for Advanced Solid Tumors
This early-phase trial tests a new drug (HS-20117) combined with other drugs for people with advanced solid tumors. It aims to see if the combination is safe and effective, especially for cancers that have not responded to other treatments.
TianjinAges 18–75 - NCT06940349RecruitingPhase 1/Phase 2
Palbociclib and sunitinib for advanced solid tumors
This study tests a combination of two oral drugs—palbociclib and sunitinib—for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these drugs together can help shrink or slow the growth of the cancer.
Petah TikvaAges 18 years+ - NCT07174661Recruiting
Planning ahead for teens and young adults with advanced cancer
This study tests an educational tool to help young adults with advanced solid tumors or high-grade brain tumors think about and discuss their future healthcare wishes early. It may help you feel more prepared and in control of your care.
Scottsdale, ArizonaAges 18–39 - NCT07167381Recruiting
Tumor testing to find cancer treatments for Florida patients
This study tests your tumor sample to find which drugs might work best for your cancer. It is for both children and adults whose cancer has come back or not responded to treatment, and who have already tried at least one standard therapy.
Miami, FloridaAges Any age - NCT07158918RecruitingPhase 1/Phase 2
Trial of ABL103 with pembrolizumab and chemo for advanced solid tumors
This trial tests a new drug called ABL103 combined with pembrolizumab (immunotherapy) and with or without a chemotherapy drug called taxane. It is for people with advanced or metastatic solid tumors that have stopped responding to standard treatments or cannot tolerate them.
Cleveland, OhioAges 18 years+ - NCT07156253RecruitingPhase 1
Study of SYN818 with olaparib for advanced solid tumors
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07128914RecruitingPhase 1
Study of GO306 for advanced solid tumors
This trial tests a new drug called GO306 for people with advanced solid tumors that have not responded to standard treatments. It may be an option if you have certain cancers like breast, bladder, colorectal, kidney, ovarian, or neuroendocrine tumors, and you have malignant ascites (fluid buildup in the belly) that needs treatment.
Hefei, AnhuiAges 18 years+ - NCT07123103RecruitingPhase 1
Study of XB371 for advanced solid tumors
This trial tests a new drug called XB371 for people with advanced solid tumors that have come back or spread. It aims to see if the drug is safe and works against the cancer.
Rogers, ArkansasAges 18 years+ - NCT05144698RecruitingPhase 1/Phase 2
RAPA-201 cell therapy for certain advanced lung and head cancers
This Phase 1/2 trial tests RAPA-201, a personalized immune cell treatment made from your own T cells, for advanced solid tumors. It may help people whose cancer has come back after standard treatment and after an anti–PD-1/PD-L1 antibody.
Hackensack, New JerseyAges 18 years+ - NCT07094204RecruitingPhase 1
Study of ASP5834 for advanced solid tumors with KRAS changes
This study tests a new drug (ASP5834) for people with advanced solid tumors that have changes in the KRAS gene. The study looks for a safe and effective dose, and may help you if your standard treatments have stopped working.
Santa Monica, CaliforniaAges 18 years+ - NCT06912152RecruitingPhase 1
Testing MT027 for advanced belly-lining cancers
This trial tests an experimental intraperitoneal therapy (MT027) for people whose advanced solid tumors have spread to the lining of the belly (peritoneum) and haven't responded to standard treatments. It aims to see if this new approach can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–70 - NCT07071090RecruitingPhase 1
Study of DC50292A for advanced solid tumors with MTAP deletion
This trial tests a new tablet, DC50292A, for people whose cancer has an MTAP gene deletion. It is for patients whose cancer has spread or returned and who have not had success with other treatments.
Fuzhou, FujianAges 18 years+ - NCT07030257RecruitingPhase 1/Phase 2
Study of CP-383 for advanced solid tumors
This study tests a new drug called CP-383 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors or slow cancer growth, especially for certain cancers with genetic changes.
Denver, ColoradoAges 18 years+ - NCT07015697RecruitingPhase 1
Study of subcutaneous trastuzumab deruxtecan for advanced solid tumors
This trial tests a form of the drug trastuzumab deruxtecan that is given as a shot under the skin for people with certain metastatic solid tumors, including breast cancer and non-small cell lung cancer with HER2 changes. It aims to see how well the shot works and if it is safe.
Newport Beach, CaliforniaAges 18 years+ - NCT07002203RecruitingPhase 1/Phase 2
Personalized cancer vaccine trial for solid tumors
This trial tests a custom-made vaccine designed to train your immune system to fight your specific cancer. It may be an option if you have advanced cancer that stopped responding to treatment or early-stage cancer with a high risk of coming back.
BangkokAges 20 years+ - NCT06992687Enrolling by invitationPhase 1/Phase 2
Study of HB0052 for advanced solid tumors
This trial tests a new drug called HB0052 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for various cancer types.
BeijingAges 18 years+ - NCT06878612RecruitingPhase 1
Personalized tumor cell vaccine for advanced solid tumors
This trial tests a new vaccine made from your own tumor cells to see if it can help your immune system fight the cancer. It is for people with advanced solid tumors that have not responded to other treatments.
Chengdu, SichuanAges 18–65 - NCT06953089RecruitingPhase 2
Combination therapy study for advanced solid tumors
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06952010RecruitingPhase 1
Study of XB628 alone and with zanzalintinib for advanced solid tumors
This trial tests a new drug, XB628, alone or together with another drug called zanzalintinib, in people whose advanced solid tumor has continued to grow after at least one prior treatment. The goal is to see if these combinations can shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+
Hear when a new Recurrent Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent solid tumor?
- Yes. Clin2 currently lists 462 recruiting recurrent solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.